Form 4 for DRMA Dermata Therapeutics, Inc.

Accepted 2025-12-29 00:00:00 ET · period of report 2025-12-23 · accession 0001493152-25-029468 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
DMI	2025-12-29	2025-12-23	DRMA	PROEHL GERALD T	Pres, COB, CEO, Dir, 10%	A - Grant	—	+612.7K	490.3K	New	—
DMI	2025-12-29	2025-12-23	DRMA	PROEHL GERALD T	Pres, COB, CEO, Dir, 10%	A - Grant	—	+1.23M	122.5K	New	—
D	2025-12-29	2025-12-23	DRMA	PROEHL GERALD T	Pres, COB, CEO, Dir, 10%	A - Grant	—	+78.7K	78.7K	New	—
D	2025-12-29	2025-12-23	DRMA	PROEHL GERALD T	Pres, COB, CEO, Dir, 10%	D - Sale to Iss	—	+78.7K	0	New	—

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2025-12-23	A	A	122,549	—	122,563	I By Sean Michael Proehl 2020 Irrevocable Trust Dated December 18, 2020	—	—	(F2) The purchase price per share of common stock and accompanying warrants was $2.04. (F3) Reflects a one-for-10 reverse stock split effected by the Issuer on August 1, 2025. (F6) Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
2	Common	Common Stock	2025-12-23	A	A	490,196	—	490,255	I By Proehl Family Trust	—	—	(F2) The purchase price per share of common stock and accompanying warrants was $2.04. (F3) Reflects a one-for-10 reverse stock split effected by the Issuer on August 1, 2025. (F6) Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
3	Derivative	Series C Warrant (Right to Buy)	2025-12-23	A	A	490,196	—	490,496	I By Proehl Family Trust	$2.04 · — to —	490,196 Common Stock	(F2) The purchase price per share of common stock and accompanying warrants was $2.04. (F6) Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. (F4) This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of Common stock issuable upon exercise of the warrants. The warrant will expire five years from the effective date of stockholder approval. The warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions.
4	Derivative	Series D Warrant (Right to Buy)	2025-12-23	A	A	490,196	—	490,496	I By Proehl Family Trust	$2.04 · — to —	490,496 Common Stock	(F2) The purchase price per share of common stock and accompanying warrants was $2.04. (F6) Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. (F5) This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants. The warrant will expire two years from the effective date of stockholder approval. The warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions.
5	Derivative	Series C Warrant (Right to Buy)	2025-12-23	A	A	122,549	—	122,549	I By Sean Michael Proehl 2020 Irrevocable Trust Dated December 18, 2020	$2.04 · — to —	122,549 Common Stock	(F2) The purchase price per share of common stock and accompanying warrants was $2.04. (F6) Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. (F4) This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of Common stock issuable upon exercise of the warrants. The warrant will expire five years from the effective date of stockholder approval. The warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions.
6	Derivative	Series D Warrant (Right to Buy)	2025-12-23	A	A	122,549	—	122,549	I By Sean Michael Proehl 2020 Irrevocable Trust Dated December 18, 2020	$2.04 · — to —	122,549 Common Stock	(F2) The purchase price per share of common stock and accompanying warrants was $2.04. (F6) Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. (F5) This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants. The warrant will expire two years from the effective date of stockholder approval. The warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions.
7	Derivative	Warrant (Right to Buy)	2025-12-23	A	A	78,740	—	78,740	D	$2.04 · — to —	78,740 Common Stock	(F3) Reflects a one-for-10 reverse stock split effected by the Issuer on August 1, 2025. (F7) In connection with the Private Placement, the Reporting Person entered into an amendment to an outstanding warrant issued on January 3, 2025, which amended the exercise price of the outstanding warrant from $12.70 to $2.04. This amendment is reported as the cancellation of the "old" warrant and the purchase of a replacement warrant. The warrant amendment transaction is exempt from Section 16(b) in accordance with Rule 16b-3(e) promulgated under the Exchange Act.
8	Derivative	Warrant (Right to Buy)	2025-12-23	D	A	78,740	—	0	D	$12.70 · — to —	78,740 Common Stock	(F3) Reflects a one-for-10 reverse stock split effected by the Issuer on August 1, 2025. (F7) In connection with the Private Placement, the Reporting Person entered into an amendment to an outstanding warrant issued on January 3, 2025, which amended the exercise price of the outstanding warrant from $12.70 to $2.04. This amendment is reported as the cancellation of the "old" warrant and the purchase of a replacement warrant. The warrant amendment transaction is exempt from Section 16(b) in accordance with Rule 16b-3(e) promulgated under the Exchange Act.